Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Diphencyprone Treatment of Alopecia Areata: Postulated Mechanism of Action and Prospects for Therapeutic Synergy with RNA Interference.

Bulock KG, Cardia JP, Pavco PA, Levis WR.

J Investig Dermatol Symp Proc. 2015 Nov;17(2):16-8. doi: 10.1038/jidsymp.2015.33.

2.

Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA.

Morrissey DV, Lee PA, Johnson DA, Overly SL, McSwiggen JA, Beigelman L, Mokler VR, Maloney L, Vargeese C, Bowman K, O'Brien JT, Shaffer CS, Conrad A, Schmid P, Morrey JD, Macejak DG, Pavco PA, Blatt LM.

J Viral Hepat. 2002 Nov;9(6):411-8.

PMID:
12431202
3.

Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA.

Macejak DG, Jensen KL, Pavco PA, Phipps KM, Heinz BA, Colacino JM, Blatt LM.

J Viral Hepat. 2001 Nov;8(6):400-5.

PMID:
11703570
4.

Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens.

Parry TJ, Bouhana KS, Blanchard KS, Pavco PA, Sandberg JA.

Curr Issues Mol Biol. 2000 Oct;2(4):113-8.

5.

Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice.

Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L, Sandberg JA.

Hepatology. 2000 Sep;32(3):640-6.

PMID:
10960462
6.

Ribozymes as tools for therapeutic target validation in arthritis.

Jarvis TC, Bouhana KS, Lesch ME, Brown SA, Parry TJ, Schrier DJ, Hunt SW 3rd, Pavco PA, Flory CM.

J Immunol. 2000 Jul 1;165(1):493-8.

7.

Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.

Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ.

Clin Cancer Res. 2000 May;6(5):2094-103.

8.

Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.

Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM.

Hepatology. 2000 Mar;31(3):769-76.

PMID:
10706571
9.

Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse.

Sandberg JA, Bouhana KS, Gallegos AM, Agrawal AB, Grimm SL, Wincott FE, Reynolds MA, Pavco PA, Parry TJ.

Antisense Nucleic Acid Drug Dev. 1999 Jun;9(3):271-7.

PMID:
10435752
10.

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.

Parry TJ, Cushman C, Gallegos AM, Agrawal AB, Richardson M, Andrews LE, Maloney L, Mokler VR, Wincott FE, Pavco PA.

Nucleic Acids Res. 1999 Jul 1;27(13):2569-77.

11.

Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint.

Flory CM, Pavco PA, Jarvis TC, Lesch ME, Wincott FE, Beigelman L, Hunt SW 3rd, Schrier DJ.

Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):754-8.

12.
14.

Structural and functional studies of the rat mitochondrial single strand DNA binding protein P16.

Hoke GD, Pavco PA, Ledwith BJ, Van Tuyle GC.

Arch Biochem Biophys. 1990 Oct;282(1):116-24.

PMID:
2221914
15.
16.

lac repressor blocks in vivo transcription of lac control region DNA.

Sellitti MA, Pavco PA, Steege DA.

Proc Natl Acad Sci U S A. 1987 May;84(10):3199-203.

17.

Supplemental Content

Loading ...
Support Center